Drugs that contain Opicapone

1. Drug name - ONGENTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8907099 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
May, 2027

(4 years from now)

US8168793 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Apr, 2029

(6 years from now)

US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(10 years from now)

CN102816157A NEUROCRINE Nitrate Group Scatechol Derivative As Comt Inhibitor
Jul, 2026

(3 years from now)

CN102816157B NEUROCRINE Nitrate Group Scatechol Derivative As Comt Inhibitor
Jul, 2026

(3 years from now)

CN101248064B NEUROCRINE Nitrate Group Scatechol Derivative As Comt Inhibitor
Jul, 2026

(3 years from now)

CN101248064A NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2026

(3 years from now)

IN268246B NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2026

(3 years from now)

IN200801612P1 NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2026

(3 years from now)

IN326913B NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O- Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

IN201401357P3 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

EP1907382A1 NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2020

(2 years ago)

EP1907382B1 NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2020

(2 years ago)

EP2791134A1 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

EP2791134B1 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors Jul, 2026

(3 years from now)

US9745290 NEUROCRINE Dosage regimen for COMT inhibitors Oct, 2027

(5 years from now)

US8524746 NEUROCRINE Dosage regimen for COMT inhibitors Jul, 2029

(6 years from now)

US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof Mar, 2030

(7 years from now)

US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof Mar, 2030

(7 years from now)

US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease May, 2035

(12 years from now)

Treatment: Method of inhibiting comt in the periphery; method of treating parkinson's disease; method of reducing o-methylation of l-dopa; Method of treating parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.